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Abstract
OBJECTIVE: To assess the efficacy and safety of Re-
duning injection for fever, rash, and ulcers in chil-
dren with mild hand, foot, and mouth disease
(HFMD).
METHODS: A stratified-block randomized, dou-
ble-blind, parallel-controlled, and multicenter clini-
cal trial was conducted with 360 patients in five
hospitals across China: Quanzhou Children's Hospi-
tal, Shijiazhuang No. 5 Hospital, Shanghai Public
Health Centre, Hunan Provincial Children's Hospi-
tal, and Kaifeng Children's Hospital. Patients were
randomized into three groups with 120 in each.
Group A was treated with Western Medicine, group
B with Reduning injection, a Chinese herbal medi-
cine, and group C with both Reduning injection
and Western Medicine. Results were compared for
treatment efficacy and safety on HFMD. The clinical
outcomes were observed as follows: fever and on-
set time of antifebrile effect (time to bring the body
temperature down ≥0.5℃ after medication); cumu-
lative time for fever recovery (body temperature re-
covering to normal and lasting more than 24 h
without medication); cumulative time for rash dis-
appearance (without new rashes or ulcers appear-
ing and the original ones fading away); and cumula-
tive time for mouth ulcer disappearance.
RESULTS: For the onset time of the antifebrile ef-
fect, there was no statistical difference between
groups A and B (P>0.05) and groups B and C (P>
0.05). However, there was a statistical difference be-
tween groups A and C (P<0.05), and the effect in
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group C was the best. For the cumulative time for
rash disappearance, there was no statistical differ-
ence between groups A and B (P>0.05). There were
statistical differences between groups A and C, and
groups B and C (P<0.05), and the effect in group C
was the best. For the cumulative time for mouth ul-
cers disappearance, there were no statistical differ-
ences among the three groups (P>0.05).
CONCLUSION: Reduning injection with Western
Medicine for symptomatic treatment is most effec-
tive for mild HFMD. No adverse reactions were ob-
served.
© 2013 JTCM. All rights reserved.
Key words: Hand, foot and mouth disease; Symp-
tomatic therapy; Randomized controlled trial; Treat-
ment outcome; Reduning injection
INTRODUCTION
Worldwide, hand, foot, and mouth disease (HFMD)
outbreaks have occurred frequently since its first report
in 1958, posing a threat to public health, especially to
children in the Asia-Pacific region.1-6 The disease can be
caused by more than 20 different enteroviruses, and its
main manifestations are fever, rashes, and ulcers in ar-
eas such as the oral mucosa and the hands, feet and
buttocks. The majority of HFMD cases are mild and
self-limited, but some will experience severe complica-
tions, including aseptic meningitis, encephalitis, pneu-
monia, myocarditis, brain-stem encephalitis, acute flac-
cid paralysis, and even death. Unfortunately, the defini-
tion and standards of the warning index system for se-
vere cases does not exist. Studies show that high fever
(body temperature >39.1℃ ) correlates with patients'
condition.7 Therefore, it could be used as a positive in-
dicator. Acute onset and rapid progression have made
early intervention and detailed observation decisive for
HFMD prognosis. At present, there is no vaccine avail-
able for HFMD treatment. According to the 2010 edi-
tion of the Chinese Ministry of Health guidelines,8 the
clinical treatment for mild cases of HFMD is symp-
tomatic relief with Western Medicine and some Chi-
nese patent medicines such as Reduning injection (Ji-
angsu Kanion Pharmaceutical LLC., Nanjing, China)
to clear heat, dispel wind, and remove toxins. We stud-
ied the clinical efficacy and safety of Reduning injec-
tion on mild HFMD.
METHODS
Subjects
This study was an ongoing clinical trial that enrolled
360 participants in five hospitals across China (Cheng-
du Infectious Disease Hospital, Shenzhen Infectious
Disease Hospital, Hangzhou Infectious Disease Hospi-
tal, Wuhan Infectious Disease Hospital, Anhui Provin-
cial Children's Hospital). Trial registration: Internation-
al clinical research registration number NCT
01175915. The protocols in this study were approved
by the Frist Affiliated Hospital of Anhui University of
Chinese Medicine Ethics Committee (Hefei, China)
(Approval ID: 2010-01). Informed consent was ob-
tained from all participants or their guardians.
Inclusion criteria: (a) met the diagnostic criteria in the
Guideline of mild HFMD (2010 Edition) issued by
Chinese Ministry of Health;8 (b) symptoms of fever
and skin lesions appearing in less than 24 h; (c) aged
1-14 years.
Exclusion criteria: (a) those with congenital organic dis-
eases, such as significant cardiovascular abnormalities,
chronic hepatitis, chronic nephritis, or blood system
diseases; (b) those with a history of allergies to herbal
medicines; (c) those suffering from with a family histo-
ry of mental illness; (d) those participating in other
clinical trials for HFMD; (e) other unpredictable fac-
tors that might cause the participant to become lost to
follow-up.
Elimination criteria: (a) participants who refused to be
randomized into any group; (b) participants who suc-
cessfully enrolled but were later found not conform to
standard; (c) participants who failed to offer any data
after enrollment; (d) participants who were reluctant to
comply with the medication (using the experimental
drugs less than three times).
The trial would be stopped if the disease rapidly deteri-
orated, posing life-threatening risks for the partici-
pants, or participants developed some serious complica-
tions and specific physiological changes which were
considered not appropriate to continue the experi-
ment. The trial was ended if patients were intolerant or
had adverse drug reactions.
Grouping
The study was a stratified-block randomized, dou-
ble-blind, parallel-controlled, and multicenter clinical
trial. All patients were randomized and administrated
by the Central Randomization System of China Acade-
my of Chinese Medical Sciences in Beijing. Each
group had 120 patients.
Treatment
All treatments were made consulting the Guidelines on
HFMD and detailed records were kept in the afore-
mentioned hospitals. Patients were separated from each
other to avoid cross-infection and ensure proper rest.
Patients ate lightly and intensive nursing of the skin
and oral cavity was given.
Treatment for group A: (a) vitamin B and C, orally; (b)
if body temperature is less than or equal to 38.5℃, give
a tepid bath or use gel sheets for physical cooling; if the
body temperature is greater than or equal to 38.5℃ ,
give ibuprofen granules (peros, 20 g/kg, taking in two
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times within one day).
Treatment for group B: (a) for patients 1-3 years old,
Reduning injection was given at 0.5 mL/kg per day
with a maximal dosage of 10 mL. Reduning injection
was diluted into 80-100 mL 5% glucose injection or
0.9% sodium chloride injection and given intravenous-
ly at 20-30 drops per min, once per day. (b) for pa-
tients 3-5 years old, Reduning injection was given at
0.5 mL/kg per day with a maximal dosage of 10 mL.
Reduning injection was diluted into 50-100 mL 5%
glucose injection or 0.9% sodium chloride injection
and given intravenously at 30-40 drops per min, once
per day. (c) for patients 6-10 years old, 10 mL Redun-
ing injection was given, once per day. Reduning injec-
tion was diluted into 100-200 mL 5% glucose injec-
tion or 0.9% sodium chloride injection and given intra-
venously at 30-60 drops per min, once per day. (d) for
patients 11-13 years old, 15 mL Reduning injection
was given, once per day. Reduning injection was dilut-
ed into 200-250 mL 5% glucose injection or 0.9% so-
dium chloride injection and given intravenously at
30-60 drops per min, once per day.
Treatment for group C: both Reduning injection and
symptomatic treatment with Western Medicines.
Ibuprofen suspension was produced by Shanghai John-
son & Johnson Pharmaceuticals (Shanghai, China). Re-
duning injection was made by Jiangsu Kanion Pharma-
ceutical (Nanjing, China).
Course: a course of treatment lasted for 3-7 days with a
3-day follow-up.
Data analysis
There is no acknowledged consensus on objective in-
dex for the treatment at present. Therefore, the chang-
es in patients' main clinical outcomes after treatments
were compared. The antifebrile working time (time to
bring body temperature down more than 0.5℃ after
medication) and the time for full fever recovery (the
body temperature recovered to lower than 37℃ and
lasted for more than 24 h without medication) were es-
pecially important. Vanishing-time of the rashes and ul-
cers on different parts of the body was also recorded
(recovery of skin was considered when there were no
rashes or ulcers emerging and the original rash disap-
peared).
Data analysis was conducted using the SAS software
(Ver. 9.1.3 SAS Institute, Chicago, IL, USA). Discrete
variables are expressed as counts (percentages) and con-
stituent ratio, continuous variables are expressed as me-
dian and means± standard deviation (SD). Differences
in the demographic and clinical characteristics of the
patient groups were assessed using the Chi-squared test
and one-way ANOVA for categorical variables.
Log-rank test, Kaplan-Meier estimates and correspond-
ing 95% confidence intervals (CI) for covariates were
applied for the final data. P<0.05 was considered statis-
tically significant.
RESULTS
Demographic characteristics and clinical
manifestations
Complete baseline data were available for 335 of 349
participants (96%). Thirteen participants were exclud-
ed: 3 from group A (1 for age of 6 months, 2 for hor-
mone use), 6 from group B (1 for antiviral medica-
tions, 5 for hormone use), and 5 from group C (1 for
age of 9 months, 3 for hormone use, 1 for being sus-
pended for observation). There were no significant dif-
ferences among the three groups (P>0.05). Patients
were 1-11 years old, with slightly more boys than girls.
Those from rural areas had a higher incidence (Table
1). The flow diagram of the trial is shown in Figure 1.
Clinical indicators
Antifebrile working time: there was no significant dif-
ference between groups A and B in statistics (P>0.05),
and there was no significant difference between groups
B and C in statistics (P>0.05). There was a significant
difference between groups C and A (P<0.05). Group C
was superior to other groups (Table 2, 3). The Ka-
plan-Meier estimate of antifebrile effect rate revealed
that group C displayed an obvious advantage over the
other two groups (Table 4, Figure 2).
Cumulative time for body temperature recovery
The log-rank test of cumulative time for body tempera-
ture recovery revealed that there was a distinct differ-
ence among the groups (P=0.045). The cumulative
time in group C (censored=36.0 h) was significantly
less than that in group A (censored=48.0 h) (P=0.020).
The cumulative time in group C (censored=36.0 h)
was also significantly less than that in group B (cen-
sored=43.0 h) (P=0.042) (Table 5, 6). Similar results
were also concluded from the Kaplan-Meier estimate
of body temperature recovery rate at any time-point:
group C was superior to groups B and A (Table 7, Fig-
ure 3).
Cumulative time for rash disappearance
The log-rank test of the cumulative time for rash disap-
pearance showed that there was a remarkable difference
among the groups (P=0.004). The cumulative time in
group C (censored=108.0 h) was superior to that in
group A (censored=120.0 h), and the difference was sig-
nificant (P=0.010). The cumulative time in group C
(censored=108.0 h) was also significantly less than that
in group B (censored=120.0 h) (P=0.003) (Table 8, 9).
In the Kaplan-Meier estimate of rash disappearance
rate at any time-point, group C was superior to groups
A and B (Table 10, Figure 4).
Cumulative time for ulcer disappearance
The log-rank test of the cumulative time for ulcer dis-
appearance showed that there was no significant differ-
ence among the three groups (P>0.05) (Tables 11-13,
Figure 5).
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Item
Gender [n (%)]
Age (years)
Height (cm)
Weight (kg)
Residence [n (%)]
Living status [n (%)]
Exposure history within 7 days [n (%)]
Highest fever temperature (℃)
Medication history [n (%)]
Allergic history [n (%)]
Past medical history [n (%)]
Temperature (℃)
Male
Female
n
Mean±SD
95% CI (L-H)
Min-Max
Median
n
Mean±SD
95% CI (L-H)
Min-Max
Median
n
Mean±SD
95% CI (L-H)
Min-Max
Median
Urban area
Township
Rural area
Others
Diaspora
Nursery
Pupil
Junior
Others
None
Exist
n
Mean±SD
95% CI (L-H)
Min-Max
Median
Chinese medicine
Western Medicine
Others
Treatment-naive
None
Once or more
None
Exit
n
Mean±SD
95% CI (L-H)
Min-Max
Median
Group A
71 (60.7)
46 (39.3)
117
2.1±1.5
1.82-2.37
1.00-8.00
2.00
105
90.5±14.3
87.73-93.27
65.00-158.00
88.00
116
13.4±4.4
12.56-14.19
7.00-45.00
12.00
23 (19.7)
30 (25.6)
64 (54.7)
0 (0.0)
93 (79.5)
21 (17.9)
3 (2.6)
0 (0.0)
0 (0.0)
92 (79.3)
24 (20.7)
116
38.5±0.6
38.39-38.59
37.30-40.00
38.50
1 (0.9)
25 (21.7)
1 (0.9)
88 (76.5)
113 (97.4)
3 (2.6)
117 (100.0)
0 (0.0)
111
38.0±0.7
37.89-38.15
36.10-40.00
38.00
69 (60.0)
46 (40.0)
115
2.2±1.7
1.89-2.51
1.00-11.00
2.00
102
90.1±12.4
87.66-92.53
65.00-135.00
88.50
114
13.6±3.6
12.91-14.27
8.00-26.00
12.75
19 (16.5)
36 (31.3)
60 (52.2)
0 (0.0)
87 (76.3)
24 (21.1)
3 (2.6)
0 (0.0)
0 (0.0)
89 (78.8)
24 (21.2)
114
38.4±0.6
38.33-38.57
37.50-40.00
38.50
0 (0.0)
22 (19.5)
1 (0.9)
90 (79.6)
111 (96.5)
4 (3.5)
111 (96.5)
4 (3.5)
111
38.0±0.6
37.92-38.13
36.50-40.00
38.00
Group B Group C
73 (63.5)
42 (36.5)
115
2.1±1.5
1.82-2.39
1.00-10.00
2.00
98
90.8±12.4
88.27-93.27
64.00-140.00
88.50
115
13.1±3.2
12.51-13.71
8.50-30.00
12.50
16 (14.0)
35 (30.7)
63 (55.3)
0 (0.0)
97 (84.3)
15 (13.0)
2 (1.7)
0 (0.0)
1 (0.9)
88 (77.2)
26 (22.8)
115
38.4±0.6
38.33-38.57
37.50-40.80
38.40
0 (0.0)
21 (18.6)
0 (0.0)
92 (81.4)
114 (99.1)
1 (0.9)
114 (99.1)
1 (0.9)
104
38.1±0.7
37.98-38.23
36.50-40.00
38.00
Table 1 Comparison of general information of the three groups
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Adverse events and safety analysis
There was an adverse event in one patient from
group A. There were no adverse events in groups B
and C. There was no statistical difference in compari-
sons among the three groups (P>0.05). There were
no adverse reactions in all three groups (Tables 14,
15).
DISCUSSION
Some herbs and their compounds can be effective
when used to prevent and cure infectious diseases.
However, their clinical application is extremely limited
because of few evidence-based clinical trials.
There is an increasing number of studies on clinical
Item
Pulse (times/min)
Respiration (times/min)
Systolic pressure (mm Hg)
Diastolic pressure (mm Hg)
n
Mean±SD
95% CI (L-H)
Min-Max
Median
n
Mean±SD
95% CI (L-H)
Min-Max
Median
n
Mean±SD
95% CI (L-H)
Min-Max
Median
n
Mean±SD
95% CI (L-H)
Min-Max
Median
Group A
117
118.8±13.5
116.39-121.32
80.00-146.00
120.00
117
27.0±4.5
26.20-27.85
19.00-40.00
26.00
107
90.4±8.1
88.82-91.93
72.00-119.00
90.00
107
57.2±7.3
55.85-58.65
38.00-85.00
60.00
115
118.6±13.4
116.10-121.05
88.00-150.00
120.00
115
27.1±4.4
26.27-27.89
20.00-42.00
28.00
108
88.8±7.2
87.39-90.13
69.00-120.00
88.50
108
56.1±7.1
54.72-57.42
39.00-88.00
57.50
Group B Group C
114
117.6±12.4
115.31-119.90
80.00-155.00
118.00
114
26.8±4.0
26.10-27.59
18.00-40.00
26.50
111
90.3±7.5
88.85-91.67
79.00-120.00
90.00
111
56.4±7.7
54.98-57.87
38.00-90.00
56.00
Notes: gender, residence, living status, exposure history within 7 days, medication history, allergic history and past medical history are cal-
culating by Chi-square test; age, height, weight, highest fever temperature, temperature, pulse, respiration, systolic pressure and diastolic
pressure are calculating by Chi-square test; group A: symptomatic treatment with Western Medicines; group B: Reduning injection; group
C: both Reduning injection and symptomatic treatment with Western Medicine. The three groups were no significant difference in gen-
der, age, height, weight, residence, living status, exposure history within 7 days, highest fever temperature, medication history, allergic his-
tory, past medical history, temperature, pulse, respiration, systolic pressure and diastolic pressure (P>0.05). P values are 0.848, 0.851,
0.934, 0.631, 0.740, 0.561, 0.922, 0.879, 0.754, 0.410, 0.070, 0.557, 0.750, 0.910, 0.221 and 0.484.
Table 1 Comparison of general information of the three groups (continued)
Cumulative time for body
temperature recovery
Cumulative time for rashes
and ulcers disappearing
Onset time of antifebrile
effect
Clinical indicators
Patients enrolled
Group A (n=117)
Patients enrolled
Group B (n=116)
Patients enrolled
Group C (n=116)
Excluded
(n=3)
Excluded
(n=6)
Excluded
(n=5)
Analyzed
(n=114)
Analyzed
(n=110)
Analyzed
(n=111)
Figure 1 Flow diagram of the trial clinical indicators
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treatments for HFMD using Traditional Chinese Medi-
cine (TCM). According to Chinese medicine theory,
the recognized pathogenesis of this disease lies in the in-
vasion of damp-heat and epidemic toxin co-existing
with the deficiency of anti-pathogenic Qi. For treat-
ment, expelling pathogenic heat, dissolving dampness,
and detoxifying should be emphasized.9-12 Reduning in-
jection is a state-level new drug in Category Ⅲ (ap-
proval number: Z20050217) with efficacy meeting
these TCM treatment criteria. It is a Chinese herbal
compound composed of three antiviral herbs, namely,
Qinghao (Herba Artemisiae Annuae), Jinyinhua (Flos
Lonicerae), and Zhizi (Fructus Gardeniae).
Prior in vitro fundamental research indicated that Re-
duning injection could inhibit the activities of Entero-
virus 71 (EV 71) and coxsackie A16 (CA 16). This re-
search provides the first comparative analysis on prevail-
ing therapies among people with mild untreated
HFMD in China. Our study is unique because its data
Item
n
Censored (%)
25% (95% CI)
50% (95% CI)
75% (95% CI)
Group A
97
9 (9.3)
1.0 (0.5-1.0)
3.0 (2.0-4.0)
8.0 (4.0-24.0)
Group B
104
16 (15.4)
0.5 (0.5-1.0)
2.0 (1.0-2.0)
6.0 (4.0-50.0)
Group C
93
5 (5.4)
0.5 (0.5-1.0)
1.0 (1.0-2.0)
4.0 (2.0-8.0)
Table 2 Quartiles of onset time (h) of antifebrile effect
Notes: group A: symptomatic treatment with Western Medicines; group B: reduning injection; group C: both Reduning injection and
symptomatic treatment with Western Medicines.
Item
Group A∶B∶C
Group A∶B
Group A∶C
Group B∶C
Statistic
4.889
0.017
4.308
3.178
DF
2
1
1
1
P
0.087
0.895
0.038
0.075
Notes: DF: dickey-fuller. Group A: symptomatic treatment with
Western Medicines; group B: reduning injection; group C: both
Reduning injection and symptomatic treatment with Western
Medicines.
Table 3 Log-rank test of onset time (h) of antifebrile effect
Item
8
16
24
32
40
48
56
64
72
Group A (%)
79.4
81.4
85.6
87.6
87.6
88.7
88.7
88.7
90.7
Group B (%)
76.0
80.8
82.7
82.7
82.7
82.7
83.7
83.7
83.7
Group C (%)
84.9
88.2
92.5
93.5
93.5
94.6
94.6
94.6
94.6
Notes: group A: symptomatic treatment with Western Medi-
cines; group B: reduning injection; group C: both Reduning in-
jection and symptomatic treatment with Western Medicines.
Table 4 Kaplan-Meier estimate of antifebrile effect rate
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
An
tife
bri
lee
ffe
ct
rat
e(
%)
0 8 16 24 32 40 48 56
Time (h)
A B C
Figure 2 Kaplan-Meier estimate of antifebrile effect rate
A: symptomatic treatment with Western Medicines; B: Re-
duning injection; C: both Reduning injection and symptom-
atic treatment withWestern Medicines.
Item
n
Censored (%)
25%
(95% CI)
50%
(95% CI)
75%
(95% CI)
Group A
97
17 (17.5)
28.0
(24.0-35.0)
48.0
(41.0-60.0)
96.0
(71.0-100.0)
Group B
104
22 (21.2)
12.0
(6.0-24.0)
43.0
(29.0-52.0)
105.0
(72.0-100.0)
Group C
93
6 (6.5)
6.0
(4.0-24.0)
36.0
(27.0-48.0)
72.0
(58.0-86.0)
Notes: group A: symptomatic treatment with Western Medi-
cines; group B: reduning injection; group C: both Reduning in-
jection and symptomatic treatment with Western Medicines.
Table 5 Quartiles of cumulative time (h) for body tempera-
ture recovery
Item
Group A∶B∶C
Group A∶B
Group A∶C
Group B∶C
Statistic
6.216
0.057
5.371
4.147
DF
2
1
1
1
P
0.045
0.811
0.020
0.042
Table 6 Log-rank test of cumulative time (h) for body tem-
perature recovery
Notes: DF: dickey-fuller. Group A: symptomatic treatment with
Western Medicines; group B: reduning injection; group C: both
Reduning injection and symptomatic treatment with Western
Medicines.
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were collected prospectively from treatment-naïve indi-
viduals at the time of entry into a clinical trial in five
cities in different geographic settings, and the therapies
were recommended by the Guidelines on HFMD. Be-
cause the participants were required to meet the uni-
form inclusion and exclusion criteria before study en-
try, the study population was more homogeneous
across geographic areas than independent cohorts.
We found that children aged 2-4 years may be most
susceptible to HFMD, perhaps because of profound
changes occurring in the body, instability of the im-
mune system, boundless energy, and outgoing personal-
ity. This may be one of the main ways of the disease.
As instability of the immune system, resistance is rela-
Item
12
24
36
48
60
72
84
96
108
120
132
144
156
168
Group A
15.5
20.6
36.1
52.6
60.8
70.1
73.2
75.3
79.4
79.4
80.4
81.4
82.5
82.5
Group B
26.0
35.6
47.1
57.7
64.4
66.3
71.2
73.1
76.9
77.9
77.9
78.8
78.8
78.8
Group C
26.9
35.5
50.5
60.2
68.8
78.5
82.8
86.0
88.2
90.3
90.3
91.4
92.5
93.5
Table 7 Kaplan-Meier estimate of body temperature recov-
ery rate at any time-point (%)
Notes: DF: dickey-fuller. Group A: symptomatic treatment with
Western Medicines; group B: reduning injection; group C: both
Reduning injection and symptomatic treatment with Western
Medicines.
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
0 12 24 36 48 60 72 84 96 108 120 132 144 156 168 180
Time (h)
Fev
er
rec
ove
ry
rat
e(
%)
A B C
Figure 3 Kaplan-Meier estimate of body temperature recovery rate at any time-point
A: symptomatic treatment with Western Medicines; B: Reduning injection; C: both Reduning injection and symptomatic treat-
ment withWestern Medicines.
Item
n
Censored (%)
25%
(95% CI)
50%
(95% CI)
75%
(95% CI)
Group A
117
18 (15.4)
96.0
(96.0-112.0)
120.0
(118.0-132.0)
144.0
(140.0-168.0)
Group B
115
24 (20.9)
96.0
(92.0-96.0)
120.0
(110.0-134.0)
179.0
(144.0-168.0)
Group C
115
9 (7.8)
82.0
(72.0-96.0)
108.0
(96.0-120.0)
144.0
(123.0-148.0)
Notes: group A: symptomatic treatment with Western Medi-
cines; group B: reduning injection; group C: both Reduning in-
jection and symptomatic treatment with Western Medicines.
Table 8 Quartiles of the cumulative time (h) for rash disap-
pearance
Item
Group A∶B∶C
Group A∶B
Group A∶C
Group B∶C
Statistic
10.98
0.254
6.588
8.996
DF
2
1
1
1
P
0.004
0.615
0.010
0.003
Notes: DF: dickey-fuller. Group A: symptomatic treatment with
Western Medicines; group B: reduning injection; group C: both
Reduning injection and symptomatic treatment with Western
Medicines.
Table 9 Log-rank test of the cumulative time (h) for rash dis-
appearance
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tively weak, so easy to be infected. Meanwhile, chil-
dren do not pay attention to personal hygiene, so easy.
Our study also discovered that this disease tended to
prevail in rural areas. China is currently a mostly agri-
cultural state, and rural residents account for the major-
ity of the total population. This population also lacks
awareness about the related prevention and isolation of
HFMD.
Body temperature was selected as a primary outcome
because it was a significant sign of deterioration of the
disease. Interestingly, we found that Reduning injec-
tion could optimize the efficacy of the drugs for symp-
tomatic treatment, since integrated therapy performed
better statistically than others. The effects included a re-
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Figure 4 Kaplan-Meier estimate of rash disappearance rate at any time-point
A: symptomatic treatment withWestern Medicines; B: reduning injection; C: both Reduning injection and symptomatic treatment
withWestern Medicines.
Item
12
24
36
48
60
72
84
96
108
120
132
144
156
168
Group A
0.0
0.0
0.0
0.9
1.7
7.7
9.4
26.5
31.6
53.8
59.8
75.2
78.6
82.9
Group B
0.0
0.0
0.0
2.6
2.6
10.4
13.0
36.5
39.1
57.4
58.3
67.8
69.6
73.0
Group C
0.0
0.0
0.0
6.1
7.8
21.7
26.1
43.5
50.4
66.1
71.3
80.9
86.1
91.3
Table 10 Kaplan-Meier estimate of rash disappearance rate
at any time-point (%)
Notes: Group A: symptomatic treatment with Western Medi-
cines; group B: reduning injection; group C: both Reduning in-
jection and symptomatic treatment with Western Medicines.
Item
n
Censored (%)
25% (95%CI)
50% (95%CI)
75% (95%CI)
Group A
112
0 (0.0)
77.0
(69.0-96.0)
115.0
(98.0-120.0)
136.0
(129.0-144.0)
Group B
110
0 (0.0)
72.0
(70.0-88.0)
98.0
(96.0-114.0)
131.0
(120.0-140.0)
Group C
105
1 (1.0)
82.0
(72.0-90.0)
108.0
(96.0-120.0)
132.0
(120.0-144.0)
Notes: group A: symptomatic treatment with Western Medi-
cines; group B: Reduning injection; group C: both Reduning in-
jection and symptomatic treatment with Western Medicines.
Table 11 Quartiles of the cumulative time (h) for ulcer disap-
pearance
Item
Group A∶B∶C
Group A∶B
Group A∶C
Group B∶C
Statistic
0.845
0.640
0.004
0.571
DF
2
1
1
1
P
0.655
0.424
0.950
0.450
Table 12 Log-rank test of the cumulative time (h) for ulcer
disappearance
Notes: DF: Dickey-Fuller. Group A: symptomatic treatment
with Western Medicines; group B: reduning injection; group C:
both Reduning injection and symptomatic treatment with West-
ern Medicines.
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duction in onset time of antifebrile effect, an accelera-
tion of body temperature recovery, and a stability of
body temperature after fever reduction.
The cumulative times for rash and ulcer disappearance
were consistent with the previous results. Group C al-
ways showed superiority over other groups. The herbal
medicines might have ingredients that act synergistical-
ly in ways we do not yet understand. Nevertheless, this
study provides an opportunity to compare the efficacy
of different treatments on patients with mild HFMD.
This study also has several limitations. The major indi-
cators of efficacy should be accurate and directional.
Item
12
24
36
48
60
72
84
96
108
120
132
144
156
168
180
192
204
216
228
240
252
Group A
0.0
0.9
1.8
11.6
13.4
23.2
28.6
39.3
47.3
63.4
70.5
85.7
89.3
96.4
98.2
100.0
100.0
100.0
100.0
100.0
100.0
Group B
0.0
0.9
1.8
8.2
10.0
27.3
32.7
49.1
55.5
70.9
76.4
89.1
90.0
97.3
98.2
99.1
99.1
100.0
100.0
100.0
100.0
Group C
0.0
0.0
1.9
5.7
6.7
21.9
30.5
43.8
52.4
69.5
76.2
87.6
90.5
94.3
97.1
99.0
99.0
99.0
99.0
99.0
99.0
Table 13 Kaplan-Meier estimate of ulcer disappearance rate
at any time-point (%)
Notes: group A: symptomatic treatment with Western Medi-
cines; group B: Reduning injection; group C: both Reduning in-
jection and symptomatic treatment with Western Medicines.
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Figure 5 Kaplan-Meier estimate
for ulcer disappearance rate at
any time-point
A: symptomatic treatment with
Western Medicines; B: Reduning
injection; C: both Reduning injec-
tion and symptomatic treatment
withWestern Medicines.
Table 15 Adverse reactions [n (%)]
Item
Exist
None
Total number
Group A
0 (0.0)
118 (100.0)
118
Group B
0 (0.0)
116 (100.0)
116
Group C
0 (0.0)
115 (100.0)
115
Notes: group A: symptomatic treatment with Western Medi-
cines; group B: Reduning injection; group C: both Reduning in-
jection and symptomatic treatment with Western Medicines.
The three groups were no significant difference in Adverse reac-
tions (P=1.000).
Table 14 Adverse events [n (%)]
Item
Exist
None
Total number
Group A
1 (0.8)
117 (99.2)
118
Group B
0 (0.0)
116 (100.0)
116
Group C
0 (0.0)
115 (100.0)
115
Notes: group A: symptomatic treatment with Western Medi-
cines; group B: Reduning injection; group C: both Reduning in-
jection and symptomatic treatment with Western Medicines.
The three groups were no significant difference in Adverse
events (P=0.376).
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Therefore body temperature, rash, and ulcers were se-
lected for observation because those symptoms have
the advantages of being simple, convenient, easily oper-
ated with strong controllability. Each symptom was an
essential prerequisite for carrying out a multicenter
clinical trial. However, there were no before-and-after
laboratory indices of the patients, as there are no recog-
nized biochemical markers for HFMD. Finally, we lack
discussion about the mechanisms of action and interac-
tion betweenWesternMedicine andReduning injection.
Despite these limitations, this study provides evidence
that the prevalence of mild HFMD is independently re-
lated to factors such as age, gender, and residence.
Therefore, integrated treatment could be the best
choice for children. These findings have significance
for the improvement of various clinical treatment pro-
grams, especially in the resource-limited countryside.
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